For media enquiries, please contact email@example.com
Conyers acted for Kiniksa Pharmaceuticals, Ltd. in respect of the Bermuda law aspects of its initial public offering of 8,477,777 Class A common shares at a price of US$18.00 per share, including 1,271,666 Class A common shares issued upon the exercise by the underwriters of their option to purchase additional shares. The gross proceeds from the offering were US$152.6 million, before deducting underwriting discounts, commissions and offering expenses. The Class A common shares began trading on the Nasdaq Global Select Market on 24 May 2018 under the ticker symbol “KNSA”.
Director Chiara Nannini and Associate Sarah Lusher of the Bermuda office and Partner Alan Dickson of the Cayman Islands Office advised on the matter.